Photo taken from Fadi Haddad/X
Mar 10, 2024, 12:31
Fadi Haddad: P1/2 study of pivekimab
Fadi Haddad, Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston, shared a post on X/Twitter:
“Out in The Lancet Oncology.
P1/2 study of pivekimab.
CD123-ADC
N=91 with R/R AML
RP2D=0.045 mg/kg q3w
TRAEs=FN, infusion reaction, anemia
ORR=21%; CRc=17%
Next step=AZA/VEN/pivekimab.”
Source: Fadi Haddad/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 5, 2024, 15:59
Nov 5, 2024, 15:51
Nov 5, 2024, 15:43
Nov 5, 2024, 15:32
Nov 5, 2024, 15:08
Nov 5, 2024, 15:06